evaluate the pharmaceuticals company wegovy on glp-1 and insurance providers Covering GLP-1 Drugs: Employers' Wegovy Now Available to Eligible

Insurance coverage is limited for both, but Wegovy may be more expensive without coverage

The data on newer agents are even more striking, with tirzepatide demonstrating significantly greater weight loss (20.2%) than semaglutide (13.7%) in head-to-head trials

Similarly, the Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Trial randomized 17,604 individuals to 2.4 mg/week semaglutide or a placebo

Both medications are taken as once-weekly subcutaneous injections and work best alongside a reduced-calorie diet and regular physical activity

2022;38(6): e3548

Conclusions This study developed pharmacodynamic models for 12 GLP-1RA drugs and conducted quantitative analyses of their time-course relationships, dose-response relationships, factors influencing efficacy, dropout rates, and adverse events